Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2846)	5/19/1999 1:04:00 PM
From: j_fir2	Respond to of 10280

Thanks so much, Peter!

To: Biomaven who wrote (2846)	5/19/1999 1:35:00 PM
From: Don Miller	Read Replies (1) \| Respond to of 10280

Thanks for the briefing. Questions for your or others detail report: 1. Were anti-take over provisions or concerns about same brought up? If so, did you get a sense of where the institutional investors might stand on this issue? 2. Was Maris there and if he was, what kinds of question did he raise.

To: Biomaven who wrote (2846)	5/19/1999 1:44:00 PM
From: AgFinder	Read Replies (1) \| Respond to of 10280

Thanks Peter ! "When you focus on single issues (like nora) you tend to forget the breadth of their development pipeline." Another problem with the media, is that aspects of the Sepracor story just cannot be fit into a 90 second soundbite ! Ag.

To: Biomaven who wrote (2846)	5/19/1999 4:48:00 PM
From: Bob Swift	Read Replies (1) \| Respond to of 10280

Peter, Thank you very much for sharing the information on the meeting. I don't quite understand what you mean by << Most excited about Meridia ICE (for indications other than obesity). Knoll (who owns Meridia) was described as "very reasonable.>> Are they in negotiation with Knoll to license the ICE ? For obesity or other indication ? I read a piece in Worth a while back which describe Meridia as being borderline effective in treatment of obesity and it has been quite a marketing effort on Knoll's part to ramp up the sale.Also I don't remember it has side effect neither, I may be wrong. Thanks.

To: Biomaven who wrote (2846)	5/23/1999 9:28:00 AM
From: Biotech Jim	Read Replies (1) \| Respond to of 10280

Concerning Meridia, etc ... I know a Knoll employee who told me that they have surpassed 1 million patients on this drug so far. Not bad for a problematic obesity treatment. Tells you a bit about the desire to have such a drug. I really wish I could look at the raw data concerning the lack of cardiovascular side effects of the active enantiomer. I just find the statement about the side effects of the racemate are mediated by the "off" enantiomer to be difficult to believe. I guess that's the scientist in me.